AVE3085
AVE3085 is a potent endothelial nitric oxide synthase enhancer, used for cardiovascular disease treatment.
Product Specifications
CAS Number
[450348-85-3]
UNSPSC
12352005
Target
NO Synthase
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/AVE-3085.html
Purity
99.42
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
O=C(C1=CC=C(OC(F)(F)O2)C2=C1)NC3CC4=C(C=CC=C4)C3
Molecular Formula
C17H13F2NO3
Molecular Weight
317.29
References & Citations
[1]Chen Y, et al. AVE 3085, a novel endothelial nitric oxide synthase enhancer, attenuates cardiac remodeling in mice through the Smad signaling pathway. Arch Biochem Biophys. 2015 Mar 15;570:8-13.|[2]Xue HM, et al. AVE3085 protects coronary endothelium from the impairment of asymmetric dimethylarginine by activation and recoupling of eNOS. Cardiovasc Drugs Ther. 2012 Oct;26 (5) :383-92.|[3]Yang Q, et al. AVE3085, an enhancer of endothelial nitric oxide synthase, restores endothelial function and reduces blood pressure in spontaneously hypertensive rats. Br J Pharmacol. 2011 Jul;163 (5) :1078-85
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-19504/AVE3085-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-19504/AVE3085-SDS-MedChemExpress.pdf
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
ENOS
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS607029-01 0.1 mL
BRCC-36 (BRCA1/BRCA2-containing Complex Subunit 36, BRCC36, BRCA1/BRCA2-containing Complex Subunit 3, BRCC3, C6.1A, CXorf53, RP11-143H17.2)
Ask
View Details MBS607029-02 5x 0.1 mL
BRCC-36 (BRCA1/BRCA2-containing Complex Subunit 36, BRCC36, BRCA1/BRCA2-containing Complex Subunit 3, BRCC3, C6.1A, CXorf53, RP11-143H17.2)
Ask
View Details